<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455608</url>
  </required_header>
  <id_info>
    <org_study_id>CTO1363</org_study_id>
    <nct_id>NCT03455608</nct_id>
  </id_info>
  <brief_title>PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer</brief_title>
  <acronym>PRO-ACTIVE</acronym>
  <official_title>PRO-ACTIVE: Comparing The Effectiveness of Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qualitative Health Research Consultants, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysphagia (difficulty swallowing) is a common and potentially life-threatening toxicity of
      radiotherapy (RT) for patients with head and neck cancer (HNC). HNC survivors have a 20-24
      percent lifetime risk of pneumonia after RT, which is associated with a 42 percent excess
      risk of death in survivorship. Moreover, dysphagia predisposes individuals to malnutrition,
      and at least half of HNC patients require feeding tubes during RT.

      Patients are commonly referred for swallowing therapy with a speech pathologist. Some
      patients receive early intervention, before a swallowing problem begins—PRO-ACTIVE therapy.
      Other patients are monitored and prescribed dysphagia interventions only if and when a
      swallowing problem occurs—RE-ACTIVE therapy. Thus, REACTIVE therapy aims to reverse an
      already impaired swallowing ability, whereas PRO-ACTIVE therapy aims to prevent or reduce
      severity of dysphagia. These two broad categories of therapy represent the most common types
      of intervention offered to HNC patients across North America. Although there is
      single-institution evidence to support each practice, it is yet unknown which is most
      effective.

      To address this gap, the primary aim of this international, multi-site 3-arm pragmatic
      randomized clinical trial is to compare the effectiveness of PRO-ACTIVE (high and low
      intensity) versus RE-ACTIVE swallowing therapy among 952 patients with HNC planning to
      undergo RT, using duration of feeding tube dependence after RT as the primary outcome. Our
      secondary aim proposes to compare the relative benefit or harm of these swallowing
      interventions on secondary outcomes considered relevant to our stakeholder partners.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Swallowing therapy is commonly provided as a behavioral treatment to lessen the risk or
      severity of dysphagia in head and neck cancer (HNC) patients; however, best practice is not
      established. This multi-site, international randomized clinical trial (RCT) will compare the
      effectiveness of PRO-ACTIVE (high and low intensity) versus RE-ACTIVE swallowing
      interventions in 952 HNC patients undergoing radiotherapy (RT). The 3 study arms represent
      alternate timing and intensity of swallowing therapy delivered by a speech language
      pathologist: 1) RE-ACTIVE, 2) PRO-ACTIVE EAT, and 3) PRO-ACTIVE EAT + EXERCISE.

      The primary aim of the PRO-ACTIVE trial is to compare the effectiveness of PRO-ACTIVE versus
      RE-ACTIVE swallowing interventions among patients with HNC planned to undergo RT. We
      hypothesize that the combined PRO-ACTIVE therapies are more effective than RE-ACTIVE therapy;
      and, if so, that more intensive PRO-ACTIVE (EAT + EXERCISE) is superior to less intensive
      PRO-ACTIVE (EAT). Effectiveness will be measured based on reduced duration of feeding tube
      dependency as the primary endpoint, an outcome valued equally by patients, caregivers and
      clinicians.

      The secondary aim of the PRO-ACTIVE trial is to compare the relative benefit or harm of
      swallowing therapy arms on secondary outcomes including videofluoroscopic swallowing
      evaluations, functional status measures, health status measures, and patient-reported
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feeding tube duration</measure>
    <time_frame>12 months</time_frame>
    <description>Effectiveness will be measured based on duration of feeding tube dependency (count of days from end of radiotherapy to last feeding tube use within the 12-month study period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The MD Anderson Dysphagia Inventory (MDADI)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of swallowing-related Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of severity or burden of cancer-related symptoms and interference with daily functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing strength</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by dynamic imaging grade of swallowing toxicity (DIGEST) pharyngeal constriction ratio (PCR) using videofluoroscopic assessment of swallow (VFS) images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Status Scale Head and Neck (PSS-HN)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of swallowing and speech performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcome of Dysphagia (MOD)</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported symptoms related to health consequences secondary to dysphagia, namely: malnutrition, aspiration pneumonia and mood changes such as depression and anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Behavior Inventory (CBI-l-V3)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of self-efficacy strategies for coping with cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-level EQ-5D version (EQ-5D-5L)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of generic quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>12 months</time_frame>
    <description>To determine weight loss, as a measure of functional status</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">952</enrollment>
  <condition>Dysphagia</condition>
  <arm_group>
    <arm_group_label>RE-ACTIVE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reactive intervention started promptly if/when dysphagia is identified (RE-ACTIVE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO-ACTIVE EAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early low intensity proactive intervention started before RT commences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRO-ACTIVE EAT + EXERCISE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early high intensity proactive intervention started before RT commences</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>RE-ACTIVE</intervention_name>
    <description>Reactive intervention started promptly if/when dysphagia is identified</description>
    <arm_group_label>RE-ACTIVE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PRO-ACTIVE EAT</intervention_name>
    <description>Early low intensity proactive intervention started before RT commences</description>
    <arm_group_label>PRO-ACTIVE EAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PRO-ACTIVE EAT + EXERCISE</intervention_name>
    <description>Early high intensity proactive intervention started before RT commences</description>
    <arm_group_label>PRO-ACTIVE EAT + EXERCISE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥ 18 years of age diagnosed with head and neck malignancy

          -  RT treatment planned for curative intent; and

          -  Dispositioned to receive external beam radiotherapy dose ≥60 gray to bilateral fields
             at participating institution

        Exclusion Criteria:

          -  Distant metastasis at enrollment; or

          -  Prior or planned total laryngectomy; or

          -  Moderate/severe dysphagia at enrollment per baseline videofluoroscopy DIGEST grade ≥2
             (as graded per central laboratory review)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosemary Martino, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kate Hutcheson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Jin</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>77072</phone_ext>
    <email>jind@smh.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Lazarus, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kate Hutcheson, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospitals and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Theurer, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>David Palma, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosemary Martino, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khalil Sultanem, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Krisciunas GP, Sokoloff W, Stepas K, Langmore SE. Survey of usual practice: dysphagia therapy in head and neck cancer patients. Dysphagia. 2012 Dec;27(4):538-49. doi: 10.1007/s00455-012-9404-2. Epub 2012 Mar 29.</citation>
    <PMID>22456699</PMID>
  </reference>
  <reference>
    <citation>Xu B, Boero IJ, Hwang L, Le QT, Moiseenko V, Sanghvi PR, Cohen EE, Mell LK, Murphy JD. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015 Apr 15;121(8):1303-11. doi: 10.1002/cncr.29207. Epub 2014 Dec 23.</citation>
    <PMID>25537836</PMID>
  </reference>
  <reference>
    <citation>Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng FY, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. Head Neck. 2014 Jan;36(1):120-5. doi: 10.1002/hed.23275. Epub 2013 Jun 1.</citation>
    <PMID>23729173</PMID>
  </reference>
  <reference>
    <citation>Hutcheson KA, Bhayani MK, Beadle BM, Gold KA, Shinn EH, Lai SY, Lewin J. Eat and exercise during radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it. JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1127-34. doi: 10.1001/jamaoto.2013.4715.</citation>
    <PMID>24051544</PMID>
  </reference>
  <reference>
    <citation>Setton J, Lee NY, Riaz N, Huang SH, Waldron J, O'Sullivan B, Zhang Z, Shi W, Rosenthal DI, Hutcheson KA, Garden AS. A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. Cancer. 2015 Jan 15;121(2):294-301. doi: 10.1002/cncr.29022. Epub 2014 Oct 6.</citation>
    <PMID>25286832</PMID>
  </reference>
  <reference>
    <citation>Mortensen HR, Jensen K, Aksglæde K, Lambertsen K, Eriksen E, Grau C. Prophylactic Swallowing Exercises in Head and Neck Cancer Radiotherapy. Dysphagia. 2015 Jun;30(3):304-14. doi: 10.1007/s00455-015-9600-y. Epub 2015 Feb 19.</citation>
    <PMID>25690840</PMID>
  </reference>
  <reference>
    <citation>Ohba S, Yokoyama J, Kojima M, Fujimaki M, Anzai T, Komatsu H, Ikeda K. Significant preservation of swallowing function in chemoradiotherapy for advanced head and neck cancer by prophylactic swallowing exercise. Head Neck. 2016 Apr;38(4):517-21. doi: 10.1002/hed.23913. Epub 2015 Jun 16.</citation>
    <PMID>25351675</PMID>
  </reference>
  <reference>
    <citation>van der Molen L, van Rossum MA, Rasch CR, Smeele LE, Hilgers FJ. Two-year results of a prospective preventive swallowing rehabilitation trial in patients treated with chemoradiation for advanced head and neck cancer. Eur Arch Otorhinolaryngol. 2014 May;271(5):1257-70. doi: 10.1007/s00405-013-2640-8. Epub 2013 Jul 28.</citation>
    <PMID>23892729</PMID>
  </reference>
  <reference>
    <citation>Carroll WR, Locher JL, Canon CL, Bohannon IA, McColloch NL, Magnuson JS. Pretreatment swallowing exercises improve swallow function after chemoradiation. Laryngoscope. 2008 Jan;118(1):39-43.</citation>
    <PMID>17989581</PMID>
  </reference>
  <reference>
    <citation>Shaw SM, Flowers H, O'Sullivan B, Hope A, Liu LW, Martino R. The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review. Dysphagia. 2015 Apr;30(2):152-75. doi: 10.1007/s00455-014-9592-z. Epub 2015 Mar 4. Review.</citation>
    <PMID>25737196</PMID>
  </reference>
  <reference>
    <citation>MD Anderson Head and Neck Cancer Symptom Working Group. Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol. 2016 Feb;118(2):304-14. doi: 10.1016/j.radonc.2016.01.019. Epub 2016 Feb 17.</citation>
    <PMID>26897515</PMID>
  </reference>
  <reference>
    <citation>Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e93-9. doi: 10.1016/j.ijrobp.2010.12.067. Epub 2011 May 17.</citation>
    <PMID>21592678</PMID>
  </reference>
  <reference>
    <citation>Hutcheson KA, Lewin JS, Barringer DA, Lisec A, Gunn GB, Moore MW, Holsinger FC. Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer. 2012 Dec 1;118(23):5793-9. doi: 10.1002/cncr.27631. Epub 2012 May 17.</citation>
    <PMID>23640737</PMID>
  </reference>
  <reference>
    <citation>Rubin EB, Buehler AE, Halpern SD. States Worse Than Death Among Hospitalized Patients With Serious Illnesses. JAMA Intern Med. 2016 Oct 1;176(10):1557-1559. doi: 10.1001/jamainternmed.2016.4362.</citation>
    <PMID>27479808</PMID>
  </reference>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.</citation>
    <PMID>26742998</PMID>
  </reference>
  <reference>
    <citation>National Cancer Institute. SEER cancer statistics factsheets: Larynx cancer. http://seer.cancer.gov/statfacts/html/laryn.html. Accessed December 12, 2016.</citation>
  </reference>
  <reference>
    <citation>Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian cancer statistics 2016. 2016; http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on. Accessed December 12, 2016.</citation>
  </reference>
  <reference>
    <citation>Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.</citation>
    <PMID>21969503</PMID>
  </reference>
  <reference>
    <citation>Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.</citation>
    <PMID>20530316</PMID>
  </reference>
  <reference>
    <citation>Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006 Feb 10;24(5):736-47. Epub 2006 Jan 9.</citation>
    <PMID>16401683</PMID>
  </reference>
  <reference>
    <citation>Roe JW, Carding PN, Rhys-Evans PH, Newbold KL, Harrington KJ, Nutting CM. Assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom - a web-based survey. Oral Oncol. 2012 Apr;48(4):343-8. doi: 10.1016/j.oraloncology.2011.11.003. Epub 2011 Nov 29.</citation>
    <PMID>22130454</PMID>
  </reference>
  <reference>
    <citation>McEwen S, Rodriguez AM, Martino R, Poon I, Dunphy C, Rios JN, Ringash J. &quot;I didn't actually know there was such a thing as rehab&quot;: survivor, family, and clinician perceptions of rehabilitation following treatment for head and neck cancer. Support Care Cancer. 2016 Apr;24(4):1449-53. doi: 10.1007/s00520-015-3021-1. Epub 2015 Nov 18.</citation>
    <PMID>26576966</PMID>
  </reference>
  <reference>
    <citation>Martino R, Beaton D, Diamant NE. Using different perspectives to generate items for a new scale measuring medical outcomes of dysphagia (MOD). J Clin Epidemiol. 2009 May;62(5):518-26. doi: 10.1016/j.jclinepi.2008.05.007. Epub 2008 Aug 22.</citation>
    <PMID>18722085</PMID>
  </reference>
  <reference>
    <citation>Nund RL, Ward EC, Scarinci NA, Cartmill B, Kuipers P, Porceddu SV. Carers' experiences of dysphagia in people treated for head and neck cancer: a qualitative study. Dysphagia. 2014 Aug;29(4):450-8. doi: 10.1007/s00455-014-9527-8. Epub 2014 May 21.</citation>
    <PMID>24844768</PMID>
  </reference>
  <reference>
    <citation>List MA, Mumby P, Haraf D, Siston A, Mick R, MacCracken E, Vokes E. Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res. 1997 Apr;6(3):274-84.</citation>
    <PMID>9226985</PMID>
  </reference>
  <reference>
    <citation>Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, Goepfert H. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6.</citation>
    <PMID>11448365</PMID>
  </reference>
  <reference>
    <citation>Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK, S Wang X, Cleeland CS. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007 Oct;29(10):923-31.</citation>
    <PMID>17358040</PMID>
  </reference>
  <reference>
    <citation>Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000 Oct 1;89(7):1634-46.</citation>
    <PMID>11013380</PMID>
  </reference>
  <reference>
    <citation>Martino R, Ringash J, Durkin L, Greco E, Huang SH, Xu W, Longo CJ. Feasibility of assessing patient health benefits and incurred costs resulting from early dysphagia intervention during and immediately after chemoradiotherapy for head-and-neck cancer. Curr Oncol. 2017 Dec;24(6):e466-e476. doi: 10.3747/co.24.3543. Epub 2017 Dec 20.</citation>
    <PMID>29270055</PMID>
  </reference>
  <reference>
    <citation>Greco E, SImic T, Ringash J, Tomlinson G, Inamoto Y, Martino R. Dysphagia treatment for patient with head and neck cancer treated with radiotherapy: A meta-analysis review. International Journal of Radiation Oncology, Biology, Physics. 2018. [Epub ahead of print]. DOI: 10.1016/j.ijrobp.2018.01.097</citation>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dysphagia</keyword>
  <keyword>swallowing disorder</keyword>
  <keyword>speech pathology</keyword>
  <keyword>swallowing therapy</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>toxicity</keyword>
  <keyword>supportive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Deglutition Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

